Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02994290 · ClinicalTrials.gov registry record · NA
Evaluation of the Implementation and Effectiveness of IPP-HPV
A NA study of HPV Vaccination, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 817
- Enrollment target
- 1
- Study location
NCT02994290: Completed NA study of HPV Vaccination, sponsored by Yale University.
NCT02994290 is a NA study of HPV Vaccination that has completed, run by Yale University. The registered enrollment target is 817 participants, above the 483-participant average among 4 other HPV Vaccination trials with a reported enrollment target (69% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02994290, a NA study of HPV Vaccination, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 817 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the proposed pilot study is to assess the implementation of IPP-HPV immunization at Yale New Haven Hospital (YNHH) and to identify potential barriers to and facilitators of this intervention to optimize its feasibility and effectiveness. It is imperative that innovative interventions be developed to achieve comprehensive utilization of this highly effective vaccine to reduce rates of HPV infection, lower rates of cervical and other HPV associated cancers, and address cancer disparities.
Primary Outcome
Data gathered via medical charts for which participants agreed to receive a dose and which did not
Conditions Studied
Interventions
- DRUG HPV vaccine
- BEHAVIORAL Inpatient Postpartum HPV Immunization Quality Improvement Program
Study Locations (1)
Connecticut
- Yale New Haven Hospital, Women's Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 817 participants |
| Start Date | 2017-01 |
| Est. Completion | 2021-10-31 |
| Phase | NA |
What the finished NCT02994290 record still lists
NCT02994290 is an interventional study that assigns participants to a tested intervention. The registered 817 participants enrollment target is mid-sized for trials with a published cap, above the 483-participant average among 4 other HPV Vaccination trials with a reported enrollment target (69% higher).
The record links to 1 condition, with HPV Vaccination appearing as the primary indexed condition, and to 2 interventions - of which HPV vaccine is the first listed.
NCT02994290 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT02994290 about?
NCT02994290 is a clinical study titled "Evaluation of the Implementation and Effectiveness of IPP-HPV". The purpose of the proposed pilot study is to assess the implementation of IPP-HPV immunization at Yale New Haven Hospital (YNHH) and to identify potential barriers to and facilitators of this intervention to optimize its feasibility and effectiveness. It is imperative that innovative interventions ...
What is the current status of trial NCT02994290?
This trial is currently completed. It is a NA study. The enrollment target is 817 participants. The study started on 2017-01. Estimated completion is 2021-10-31.
What conditions does trial NCT02994290 study?
This clinical trial studies the following conditions: HPV Vaccination.
What interventions are being tested in trial NCT02994290?
The interventions under investigation include: HPV vaccine (DRUG), Inpatient Postpartum HPV Immunization Quality Improvement Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT02994290?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02994290 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HPV Vaccination
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Culturally Targeted Health Communication and Receptivity to the Human Papillomavirus Vaccine Among Parents in Flint, MI
RECRUITING · NA
-
OPERATION WIPE OUT: Multi-Channel Communication Campaign to Promote HPV Vaccination in Chambers County, Alabama
ACTIVE NOT RECRUITING · NA
-
PREVENT HPV -Related Cancers Trial
ACTIVE NOT RECRUITING · NA
-
Trial of a Social Marketing Campaign to Increase HPV Vaccination Among Mexican American Children
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04846959 · 818 participants
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
- NCT07218029 · 815 participants · Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
- NCT04028687 · 820 participants
MDR - PMCF Study for Taperloc Complete Stems
- NCT04613440 · 820 participants · NA
FaCT Trial (Facilitated Cascade Testing Trial)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia